Charles River Laboratories Intl. Inc vs Jumia Technologies AG - ADR — how do they compare? Charles River Laboratories Intl. Inc trades at $228.01 (market cap $11.14B), while Jumia Technologies AG - ADR trades at $6.95 (market cap $848.39M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 13.1× Jumia Technologies AG - ADR's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals.
| CRL | JMIA | |
|---|---|---|
Market Cap | $11.14B | $848.39M |
Sector | Health | Consumer Cyclical |
52-Week High | $233.60 | $14.60 |
52-Week Low | $145.57 | $4.45 |
Enterprise Value | $14.00B | $795.49M |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
JMIA trades at $6.71, down 4.28% today, amid bearish technical signals despite analyst optimism. The company shows improving fundamentals with revenue growth to $189M in 2025 and narrowing losses, targeting 2027 profitability. Recent Q1 2026 results beat GMV guidance with 39% revenue growth, though EPS missed expectations. Cash flow turned positive in 2024-2025 after years of negative net flows.
Outlook remains speculative with high execution risk despite 71% analyst buy ratings. The path to profitability depends on successful African market expansion and cost management. Key risks include persistent losses, competitive pressures, and macroeconomic challenges in operating markets.
Trailing returns across standard periods
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →